PAQ Therapeutics Raises $39M in Series B Financing

PAQ Therapeutics Announces $39 Million Series B Financing and Initiates Phase 1 Trial to Advance Novel Approach Addressing KRAS-Driven Cancers with High Unmet Need

/PRNewswire/ -- PAQ Therapeutics, a biotechnology company developing best- and first-in-class KRAS degraders for patients with lethal cancers lacking effective...

PAQ Therapeutics Raises $39M in Series B Financing

PAQ Therapeutics, a Burlington, MA-based biotechnology company developing KRAS degraders, raised $39M in Series B funding. The round was led by Bayland Capital and MRL Ventures Fund (MRLV), with participation from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), LAV Fund, BioTrack Capital, and existing investor Sherpa Health Partners. The company intends to use the […] The post PAQ Therapeutics Raises $39M in Series B Financing appeared first o…